OCEA-001 (anti-CSPG4 mAb)
Non-Small Cell Lung Cancer (NSCLC), Melanoma
Key Facts
About Ocean Biomedical
Ocean Biomedical is a biopharmaceutical company focused on translating groundbreaking academic research into novel therapeutics. Its strategy involves in-licensing and developing a diversified pipeline of drug candidates targeting oncology, fibrosis, and infectious diseases. The company went public via a SPAC merger in 2023, providing capital to advance its lead programs into clinical development. Its approach centers on identifying and validating new biological pathways to create first-in-class or best-in-class treatments.
View full company profileAbout Ocean Biomedical
Ocean Biomedical is a biopharmaceutical company focused on translating groundbreaking academic research into novel therapeutics. Its strategy involves in-licensing and developing a diversified pipeline of drug candidates targeting oncology, fibrosis, and infectious diseases. The company went public via a SPAC merger in 2023, providing capital to advance its lead programs into clinical development. Its approach centers on identifying and validating new biological pathways to create first-in-class or best-in-class treatments.
View full company profile